Resiquimod

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Resiquimod
Resiquimod2DCSD.svg
Systematic (IUPAC) name
1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
Clinical data
Legal status
  • Investigational
Routes Topical
Identifiers
CAS number 144875-48-9 YesY
ATC code None
PubChem CID 159603
ChemSpider 140330 N
UNII V3DMU7PVXF N
ChEMBL CHEMBL383322 N
Chemical data
Formula C17H22N4O2 
Mol. mass 314.382 g/mol
 N (what is this?)  (verify)

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical cream in the treatment of skin lesions[1] such as those caused by the herpes simplex virus,[2][3] and as an adjuvant to increase the effectiveness of vaccines.[4] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,[5] and an upregulator of the opioid growth factor receptor.[6]

See also[edit]

References[edit]

  1. ^ Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (July 2008). "A phase II dose-ranging study of topical resiquimod to treat actinic keratosis". The British Journal of Dermatology 159 (1): 205–10. doi:10.1111/j.1365-2133.2008.08615.x. PMID 18476957. 
  2. ^ Wu JJ, Huang DB, Tyring SK (November 2004). "Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses". Antiviral Research 64 (2): 79–83. doi:10.1016/j.antiviral.2004.07.002. PMID 15498602. 
  3. ^ Fife KH, Meng TC, Ferris DG, Liu P (February 2008). "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions". Antimicrobial Agents and Chemotherapy 52 (2): 477–82. doi:10.1128/AAC.01173-07. PMC 2224757. PMID 18039918. 
  4. ^ Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (October 2007). "Resiquimod and other immune response modifiers as vaccine adjuvants". Expert Review of Vaccines 6 (5): 835–47. doi:10.1586/14760584.6.5.835. PMID 17931162. 
  5. ^ Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (February 2009). "TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells". Immunobiology 214 (8): 683–91. doi:10.1016/j.imbio.2008.12.003. PMID 19249118. 
  6. ^ Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (August 2008). "Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function". Experimental Biology and Medicine (Maywood, N.J.) 233 (8): 968–79. doi:10.3181/0802-RM-58. PMID 18480416.